PH12023552004A1 - Attenuated african swine fever virus and its use as a vaccine - Google Patents
Attenuated african swine fever virus and its use as a vaccineInfo
- Publication number
- PH12023552004A1 PH12023552004A1 PH1/2023/552004A PH12023552004A PH12023552004A1 PH 12023552004 A1 PH12023552004 A1 PH 12023552004A1 PH 12023552004 A PH12023552004 A PH 12023552004A PH 12023552004 A1 PH12023552004 A1 PH 12023552004A1
- Authority
- PH
- Philippines
- Prior art keywords
- virus
- attenuated
- asf
- present
- swine fever
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title abstract 7
- 241000701386 African swine fever virus Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000007407 African swine fever Diseases 0.000 abstract 10
- 241000700605 Viruses Species 0.000 abstract 9
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000282887 Suidae Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000011081 inoculation Methods 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305138.6A EP4036226A1 (en) | 2021-02-02 | 2021-02-02 | Attenuated african swine fever virus and its use as a vaccine |
| PCT/EP2022/052183 WO2022167360A1 (en) | 2021-02-02 | 2022-01-31 | Attenuated african swine fever virus and its use as a vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12023552004A1 true PH12023552004A1 (en) | 2023-12-04 |
Family
ID=74661313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2023/552004A PH12023552004A1 (en) | 2021-02-02 | 2022-01-31 | Attenuated african swine fever virus and its use as a vaccine |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115851623A (zh) * | 2022-12-27 | 2023-03-28 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟mgf505-2r基因缺失减毒株的构建及作为疫苗的应用 |
| CN118091160B (zh) * | 2024-03-09 | 2025-06-06 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 一种非洲猪瘟病毒抗体的ipma检测方法与试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR682468A (fr) | 1928-12-13 | 1930-05-28 | Gas Fire Extinguisher Corp Du | Extincteur d'incendie |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9528094B2 (en) | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
| CN110093324B (zh) * | 2019-04-26 | 2020-02-18 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 基因缺失的减毒非洲猪瘟病毒及其作为疫苗的应用 |
-
2021
- 2021-02-02 EP EP21305138.6A patent/EP4036226A1/en not_active Withdrawn
-
2022
- 2022-01-31 CA CA3207287A patent/CA3207287A1/en active Pending
- 2022-01-31 WO PCT/EP2022/052183 patent/WO2022167360A1/en not_active Ceased
- 2022-01-31 PH PH1/2023/552004A patent/PH12023552004A1/en unknown
- 2022-01-31 KR KR1020237029446A patent/KR20230141819A/ko active Pending
- 2022-01-31 US US18/264,040 patent/US20240123048A1/en active Pending
- 2022-01-31 EP EP22703602.7A patent/EP4288526A1/en active Pending
- 2022-01-31 CN CN202280016288.4A patent/CN117295815A/zh active Pending
- 2022-01-31 JP JP2023570333A patent/JP2024504878A/ja active Pending
- 2022-01-31 BR BR112023015579A patent/BR112023015579A2/pt unknown
- 2022-01-31 MX MX2023008932A patent/MX2023008932A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504878A (ja) | 2024-02-01 |
| MX2023008932A (es) | 2023-10-10 |
| US20240123048A1 (en) | 2024-04-18 |
| WO2022167360A1 (en) | 2022-08-11 |
| BR112023015579A2 (pt) | 2023-11-14 |
| CN117295815A (zh) | 2023-12-26 |
| EP4036226A1 (en) | 2022-08-03 |
| CA3207287A1 (en) | 2022-08-11 |
| KR20230141819A (ko) | 2023-10-10 |
| EP4288526A1 (en) | 2023-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quinn et al. | Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle | |
| Früh et al. | CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination | |
| Snyder et al. | Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells | |
| Sanford et al. | Deletion of the thymidine kinase gene induces complete attenuation of the Georgia isolate of African swine fever virus | |
| US10537621B2 (en) | Vaccine comprising beta-herpesvirus | |
| Liu et al. | Research progress on live attenuated vaccine against African swine fever virus | |
| Slavuljica et al. | Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties | |
| US20150165018A1 (en) | Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals | |
| Neff et al. | Characterization of western European field isolates and vaccine strains of avian infectious laryngotracheitis virus by restriction fragment length polymorphism and sequence analysis | |
| MX2023008932A (es) | Virus atenuado de la peste porcina africana y su uso como vacuna. | |
| CN108064304A (zh) | 可用于产生非典型cd8+ t细胞应答的方法和组合物 | |
| Lee et al. | Growth kinetics and transmission potential of existing and emerging field strains of infectious laryngotracheitis virus | |
| Wang et al. | The first complete genome sequence and pathogenicity characterization of fowl adenovirus 11 from chickens with inclusion body hepatitis in Pakistan | |
| CN104561092A (zh) | 表达猪瘟病毒e2蛋白重组prrs病毒基因工程疫苗的构建方法和应用 | |
| CN106939320B (zh) | 一种伪狂犬病毒js-2012株感染性克隆质粒、构建方法与应用 | |
| Liu et al. | Construction of recombinant HVT expressing PmpD, and immunological evaluation against Chlamydia psittaci and Marek’s disease virus | |
| Binjawadagi et al. | Development of a porcine reproductive and respiratory syndrome virus-like-particle-based vaccine and evaluation of its immunogenicity in pigs | |
| Moriyama et al. | SARS-CoV-2 Omicron subvariants evolved to promote further escape from MHC-I recognition | |
| Su et al. | A recombinant field strain of Marek's disease (MD) virus with reticuloendotheliosis virus long terminal repeat insert lacking the meq gene as a vaccine against MD | |
| JP7703030B2 (ja) | 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失 | |
| Cavadini et al. | Molecular characterization of SG33 and Borghi vaccines used against myxomatosis | |
| WO2022090131A1 (en) | Recombinant african swine fever virus as live attenuated vaccine against african swine fever | |
| Taus et al. | Malignant catarrhal fever in American bison (Bison bison) experimentally infected with alcelaphine herpesvirus 2 | |
| JP2024504878A5 (cg-RX-API-DMAC10.html) | ||
| Tran et al. | Evaluation of the vaccine candidate ASFV-MEC-01: safety, efficacy, transmission dynamics, and assessment of reversion to virulence |